Statements and Responses
Read our submitted letters to editors and responses to Amgen news.
-
08.16.2022
Statement on Drug Pricing Provisions Included in “Inflation Reduction Act” -
06.01.2022
Amgen Statement on Russia/Ukraine -
07.12.2021
Amgen Supports Industry Efforts to Address Global Access to COVID-19 Vaccines -
11.17.2020
Amgen Proudly Supports PhRMA’s New Principles on Clinical Trial Diversity -
07.20.2020
Oklahoma Health Care Authority and Amgen Enter into Value-Based Contract for Enbrel® (etanercept) -
05.07.2020
Amgen Comments On the Supreme Court of Japan Ruling
On PCSK9 Patent Infringement Litigation
-
10.18.2019
Amgen Comments on ICER’s Proposed Changes to the 2020 Value Assessment Framework
-
09.09.2019
Amgen Comments on ICER’s Proposed Methods Adaptations For Assessments of Potential Cures and Other Transformative Therapies
-
09.04.2019
Amgen Response in Support of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias
-
07.11.2019
Amgen Comments on PCSK9 Patent Litigation in Germany
-
06.17.2019
Amgen Comments for ICER’s 2020 Value Assessment Framework
-
06.14.2019
Helping Patients Understand the Price of Their Medicines
-
05.02.2019
Amgen Reaches Settlement With Coherus in Trade Secrets Case Regarding Pegfilgrastim
-
04.25.2019
Amgen Reaches Settlement Agreement To Resolve Allegations Related To Patient Assistance Programs
-
02.21.2019
Amgen’s Comments on ICER’s Value-Based Price Of A Cure Collaborative: Methodological Considerations
-
02.13.2019
Amgen’s Comments on ICER’s Price Increase Draft Protocol